More on Shingles Vaccine From Non Pharma Research

Models predicted that the recombinant subunit zoster vac- cine (Shingrix) is likely cost-effective in Canada for adults 60 years or older and that it provides greater health benefits than the live attenu- ated zoster (Zostrix) vaccine for all age groups.